Do you want to read an article? Please log in or register.
Risk factors for disease progression in idiopathic pulmonary fibrosis
Pulmonary Fibrosis
RECOMMENDED
Related content
RECOMMENDED
Pulmonary Fibrosis
Telomere length and risk of idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease: a mendelian randomisation study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med.
Duckworth A, Gibbons MA, Allen RJ, Almond H, Beaumont RN, Wood AR, Lunnon K, Lindsay MA, Wain LV, Tyrrell J, Scotton CJ
doi: 10.1016/S2213-2600(20)30364-7.Visit the original publication at ncbi.nlm.nih.gov
RECOMMENDED
Pulmonary Fibrosis
Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and is independent of radiological disease extent
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Eur Respir J.
Invernizzi R, Barnett J, Rawal B, Nair A, Ghai P, Kingston S, Chua F, Wu Z, Wells AU, Renzoni ER, Nicholson AG, Rice A, Lloyd CM, Byrne AJ, Maher TM, Devaraj A, Molyneaux PL
doi: 10.1183/13993003.01519-2019.
Pulmonary Fibrosis
Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study
Lancet Respir Med.
Herazo-Maya JD, Sun J, Molyneaux PL, Li Q, Villalba JA, Tzouvelekis A, Lynn H, Juan-Guardela BM, Risquez C, Osorio JC, Yan X, Michel G, Aurelien N, Lindell KO, Klesen MJ, Moffatt MF, Cookson WO, Zhang Y, Garcia JGN, Noth I, Prasse A, Bar-Joseph Z, Gibson KF, Zhao H, Herzog EL, Rosas IO, Maher TM, Kaminski N
doi: 10.1016/
Idiopathic pulmonary fibrosis in a Swiss interstitial lung disease reference centre
Swiss Med Wkly.
Guler S, Zumstein P, Berezowska S, Pöllinger A, Geiser T, Funke-Chambour M
doi: 10.4414/smw.2018.14577.
Pulmonary Fibrosis
Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?
Lancet Respir Med.
Johannson KA, Strâmbu I, Ravaglia C, Grutters JC, Valenzuela C, Mogulkoc N, Luppi F, Richeldi L, Wells AU, Vancheri C, Kreuter M; Erice ILD Working Group
doi: 10.1016/
COMMENTED
Pulmonary Fibrosis
Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials
Lancet Respir Med.
Neighbors M, Cabanski CR, Ramalingam TR, Sheng XR, Tew GW, Gu C, Jia G, Peng K, Ray JM, Ley B, Wolters PJ, Collard HR, Arron JR
doi: 10.1016/
RECOMMENDED
Pulmonary Fibrosis
Impaired Cytomegalovirus Immunity in Idiopathic Pulmonary Fibrosis Lung Transplant Recipients with Short Telomeres
Am J Respir Crit Care Med.
Popescu I, Mannem H, Winters SA, Hoji A, Silveira F, McNally E, Pipeling MR, Lendermon EA, Morrell MR, Pilewski JM, Hanumanthu VS, Zhang Y, Gulati S, Shah PD, Iasella CJ, Ensor CR, Armanios M, McDyer JF
doi: 10.1164/rccm.
Pulmonary Fibrosis
Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
EBioMedicine.
Justice JN, Nambiar AM, Tchkonia T, LeBrasseur NK, Pascual R, Hashmi SK, Prata L, Masternak MM, Kritchevsky SB, Musi N, Kirkland JL
doi: 10.1016/j.ebiom.2018.12.052.
RECOMMENDED
Interstitial Lung DiseasePulmonary Fibrosis
Prognostic value of transbronchial lung cryobiopsy for the multidisciplinary diagnosis of idiopathic pulmonary fibrosis: a retrospective validation study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med.
Tomassetti S, Ravaglia C, Wells AU, Cavazza A, Colby TV, Rossi G, Ley B, Ryu JH, Puglisi S, Arcadu A, Marchi M, Sultani F, Martinello S, Donati L, Gurioli C, Gurioli C, Tantalocco P, Hetzel J, Dubini A, Piciucchi S, Klersy C, Lavorini F, Poletti V
doi: 10.1016/S2213-2600(20)30122-3.